[ad_1]
Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd, has introduced Shreehas Tambe, Deputy CEO of Biocon Biologics, as the brand new Managing Director and CEO of the corporate efficient December 5, 2022. Tambe will lead BBL in realising its aim of being a worldwide biosimilars chief, the corporate mentioned.
Tambe has taken over from Arun Chandavarkar, who continues to function a non-Govt, non-Impartial Director on the Board of Biocon Biologics. Tambe performed an essential and really efficient position in supporting Arun Chandavarkar since March 2021.
Kiran Mazumdar-Shaw, Govt Chairperson, Biocon & Biocon Biologics, mentioned: “This can be very pleasing that Shreehas is taking up the duty of main Biocon Biologics as MD & CEO at a time when the corporate is gearing up for international management in biosimilars with the closing of the Viatris acquisition. She added that Shreehas shall be aided by a extremely skilled Govt Management Crew in constructing a futureready, world main biosimilars participant and a well-recognized international model that’s dedicated to affect international healthcare.”
Tambe mentioned he “is deeply humbled and honored by the arrogance that the Board of Biocon Biologics has reposed in him to steer the corporate”.
He talked about how the latest acquisition of Viatris’ international biosimilars enterprise is a recreation altering occasion in Biocon’s journey. “Undoubtedly these are thrilling instances, and along with an distinctive crew, I’m wanting ahead to main Biocon Biologics within the subsequent part of progress,” Tambe mentioned.
About Chandavarkar’s contributions, Mazumdar-Shaw thanked Arun for his large contributions to the Biocon Group and Biocon Biologics over the previous three many years.
She acknowledged that beneath his management, Biocon Biologics has made speedy strides in the direction of realizing its strategic aim of being a worldwide chief in biosimilars. “He led the Firm’s restoration from pandemic-related setbacks and steered the group again onto the trail of sustainable progress. I sit up for his lively contributions to the BBL Board,” she mentioned
Arun Chandavarkar, the outgoing MD, Biocon Biologics, mentioned it has been his “privilege to have led Biocon Ltd and now, Biocon Biologics by means of many pivotal moments and pioneering achievements over the three-decade affiliation with the corporate”.
Tambe holds a Masters’ diploma in Bioprocess Know-how from ICT (UDCT), College of Mumbai and has additionally studied Pharmaceutical Sciences & Know-how on the College of Pune. He was conferred the coveted Distinguished Alumnus Award (Skilled) by his alma mater, the celebrated ICT, Mumbai, in 2020.
On Monday, the corporate’s scrip on BSE closed 1.5% decrease at Rs 279.
Additionally learn: Biocon Biologics To Shut Viatris Deal Quickly, IPO Plan Possible In 12-24 Months
Additionally learn: John Shaw, former Biocon VC and Kiran Mazumdar-Shaw’s husband, passes away
Source link